Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls

Mar 19 2020

• By Joseph Haas

Business people looking at screen during video conference in office — Recent biopharma earnings calls have detailed varying impacts of the coronavirus pandemic

Related Content

Dsuvia: A Dull US FDA Review Preceded The Controversial Approval

Jul 16 2019

Baxter Injects $625m In ‘Foundational Asset’ Claris

Dec 16 2016

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Feb 28 2020

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Feb 26 2020

Bad For Pharma: Sales Reps And Patients Are Staying Home

Mar 18 2020

Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist

Mar 19 2020

Video Interview: Abeona Breaking Into Rare Diseases

Feb 12 2016

Cormedix Leads Limited Pipeline For US FDA’s LPAD Pathway

Mar 11 2020

Arikayce’s Limited Population, Black Box Warning Won’t Limit Launch, Insmed Says

Oct 03 2018

Related Companies

Baxter International Inc.

Insmed Incorporated

Athersys, Inc.

Talphera, Inc.

Catalyst Pharmaceuticals, Inc.

CorMedix Inc.

Abeona Therapeutics Inc.

Additional Topics

Coronavirus COVID-19 Sales & Earnings Business Strategies Manufacturing Companies Commercial Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window